Natural history of liver adenomatosis: a long-term observational study.

[1]  M. Nikolski,et al.  Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk , 2017, Hepatology.

[2]  O. V. van Delden,et al.  Systematic review of transarterial embolization for hepatocellular adenomas , 2017, The British journal of surgery.

[3]  S. Imbeaud,et al.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. , 2017, Gastroenterology.

[4]  N. Demartines,et al.  European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  F. Pruvot,et al.  Liver transplantation for adenomatosis: European experience , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  C. Sempoux,et al.  Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. , 2015, Journal of hepatology.

[7]  Jessica Zucman-Rossi,et al.  Hepatocellular benign tumors-from molecular classification to personalized clinical care. , 2013, Gastroenterology.

[8]  C. Sempoux,et al.  Pathological Diagnosis of Hepatocellular Cellular Adenoma according to the Clinical Context , 2013, International journal of hepatology.

[9]  H. D. de Koning,et al.  Pregnancy and liver adenoma management: PALM-study , 2012, BMC Gastroenterology.

[10]  V. Paradis,et al.  Changing trends in malignant transformation of hepatocellular adenoma , 2010, Gut.

[11]  J. Tran van Nhieu,et al.  Spectrum of HNF1A Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With MODY3 and Suggests Genotoxic Damage , 2010, Diabetes.

[12]  V. Paradis,et al.  A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. , 2009, Gastroenterology.

[13]  J. Zucman‐Rossi,et al.  Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience , 2009, Hepatology.

[14]  J. Zucman‐Rossi,et al.  Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification , 2008, Hepatology.

[15]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[16]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[17]  C. de Toma,et al.  Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. , 2007, Cancer research.

[18]  J. Zucman‐Rossi,et al.  Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. , 2003, Gastroenterology.

[19]  S. Rich,et al.  Genetic modifiers of the age at diagnosis of diabetes (MODY3) in carriers of hepatocyte nuclear factor-1alpha mutations map to chromosomes 5p15, 9q22, and 14q24. , 2003, Diabetes.

[20]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[21]  Claude Degott,et al.  Liver adenomatosis. An entity distinct from liver adenoma? , 1985, Gastroenterology.

[22]  J. Foster,et al.  Familial liver-cell adenomas and diabetes mellitus. , 1978, The New England journal of medicine.

[23]  J. Hallgrímsson,et al.  Multiple Adenoma (Hamartoma) of the Liver Treated by Subtotal (90%) Resection: Morphological and Functional Studies of Regeneration , 1964 .

[24]  H. Reeves.  EASL Clinical Practice Guidelines on the management of benign liver tumours. , 2016, Journal of hepatology.

[25]  J. Zucman‐Rossi,et al.  Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. , 2008, Journal of hepatology.